Coherus Oncology (CHRS) Cash & Equivalents Growth (3y) (2016 - 2026)

Coherus Oncology (CHRS) Cash & Equivalents Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -8.88%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Coherus Oncology 194.37 Mn 27.32 Mn 8.50 Mn 92.54%

Historic Data

Download Data
DateValue
Mar 31, 2026 92.54%
Dec 31, 2025 11.83%
Sep 30, 2025 -28.84%
Jun 30, 2025 -7.66%
Mar 31, 2025 -36.75%
Dec 31, 2024 -32.91%
Sep 30, 2024 -35.29%
Jun 30, 2024 -21.54%
Mar 31, 2024 0.04%
Dec 31, 2023 -42.50%
Sep 30, 2023 -35.02%
Jun 30, 2023 -31.27%
Mar 31, 2023 -56.28%
Dec 31, 2022 -29.02%
Sep 30, 2022 20.21%
Jun 30, 2022 37.52%
Mar 31, 2022 58.68%
Dec 31, 2021 79.32%
Sep 30, 2021 52.73%
Jun 30, 2021 1,775.28%